Innate Pharma (IPH) — Defensive Interval Ratio

Latest as of December 2025: 465 days

Innate Pharma (IPH) has a Defensive Interval Ratio of 465 days as of December 2025. Defensive assets of €46.71 Million (cash €28.09 Million, short-term investments €6.22 Million, receivables €12.40 Million) cover 465 days of daily cash needs of €100.41K/day. Check Innate Pharma (IPH) tangible equity ratio to evaluate the tangible quality of the company's equity base.

Defensive Interval Ratio

465 days
Days of operational coverage

Defensive Assets

€46.71 Million
Cash + ST Investments + Receivables

Daily Cash Need

€100.41K
Current Liabilities ÷ 365

Current Liabilities

€36.65 Million
EUR

Innate Pharma Defensive Interval Ratio (2003–2025)

This chart shows how Innate Pharma's Defensive Interval Ratio has evolved across 23 annual periods from 2003 to 2025. As of December 2025, the ratio stands at 465 days, meaning defensive assets of €46.71 Million can fund 465 days of operations without new revenue. Also explore Innate Pharma (IPH) equity growth momentum to track the company's year-over-year net asset growth rate.

Annual Defensive Interval Ratio for Innate Pharma (2003–2025)

The table below presents the year-by-year Defensive Interval Ratio for Innate Pharma from 2003 to 2025, covering 23 annual filings. Each row shows defensive assets, daily cash need, the DIR in days, and the change in days compared to the prior year. For live market cap and the full company financial profile, see how much is Innate Pharma worth.

Year DIR (days) Defensive Assets (EUR) Daily Cash Need Cash ST Investments Change (days)
2025 465 days €46.71 Million €100.41K/day €28.09 Million €6.22 Million ▼ -484 days
2024 949 days €85.74 Million €90.36K/day €66.40 Million €14.37 Million ▼ -331 days
2023 1279 days €138.94 Million €108.59K/day €70.61 Million €21.85 Million ▲ +110 days
2022 1170 days €132.50 Million €113.25K/day €84.22 Million €17.26 Million ▲ +538 days
2021 632 days €138.26 Million €218.87K/day €103.76 Million €16.08 Million ▼ -723 days
2020 1355 days €173.33 Million €127.93K/day €136.79 Million €14.85 Million ▲ +691 days
2019 664 days €221.68 Million €333.76K/day €202.89 Million €15.98 Million ▲ +81 days
2018 583 days €314.17 Million €539.01K/day €152.31 Million €15.22 Million ▲ +426 days
2017 157 days €31.83 Million €202.49K/day €- €16.74 Million ▼ -69 days
2016 226 days €47.34 Million €209.43K/day €0.00 €21.78 Million ▼ -338 days
2015 564 days €92.99 Million €164.83K/day €- €83.04 Million ▲ +363 days
2014 201 days €5.93 Million €29.52K/day €- €4.95 Million ▼ -11 days
2013 212 days €5.39 Million €25.42K/day €- €2.99 Million ▲ +94 days
2012 118 days €4.98 Million €42.09K/day €- €2.03 Million ▼ -17 days
2011 136 days €5.75 Million €42.45K/day €- €- ▼ -254 days
2010 390 days €7.87 Million €20.20K/day €- €2.76 Million ▲ +46 days
2009 344 days €8.73 Million €25.38K/day €- €2.75 Million ▼ -704 days
2008 1048 days €36.81 Million €35.12K/day €- €22.95 Million ▼ -704 days
2007 1752 days €50.62 Million €28.89K/day €- €48.30 Million ▼ -450 days
2006 2202 days €60.54 Million €27.50K/day €- €53.66 Million ▼ -1000 days
2005 3201 days €19.82 Million €6.19K/day €- €15.76 Million ▼ -1758 days
2004 4959 days €27.80 Million €5.61K/day €- €24.85 Million ▲ +526 days
2003 4433 days €18.55 Million €4.18K/day €- €14.47 Million —
DIR = (Cash + Short-term Investments + Net Receivables) / (Daily Cash Expenses)